openalexZenodo (CERN European Organization for Nuclear Research)2026-07-23
Computational Patient Selection for Extracellular Matrix Therapies: A Machine Learning Framework for Phase II Trial Optimization
Live Interactive Clinical Interface: https://ventrigelcds.streamlit.app/ Abstract: Phase II cardiovascular trials fail frequently because of patient heterogeneity and high capital costs, with only an estimated 25 percent of cardiovascular drugs successfully transitioning to Phase…